Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
OBJECTIVES: To test whether patients with clinical Stage T2a prostate cancer with biopsy-proven disease only contralateral to the palpable abnormality experience outcomes similar to those of patients with clinical Stage T1c. METHODS: We identified 1567 patients who had undergone radical prostatectomy at our institution from 1995 to 2007 with a prostate-specific antigen level of less than 10 ng/mL and complete information regarding the laterality of positive biopsy cores. Of these patients, 1157 had clinical Stage T1c and 410 Stage cT2a. The patients with clinical Stage T2a were divided into two groups according to the laterality of the positive biopsy cores: ipsilateral only (n = 241) and contralateral only (n = 53). Kaplan-Meier analyses were used to compare the biochemical recurrence-free survival (BRFS) probabilities. RESULTS: The patients with clinical Stage T2a had significantly poorer 5-year BRFS than did the patients with clinical Stage T1c (83.5% versus 94.4%, P <0.001). The di
Related Questions
- Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
- Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?
- Does needle biopsy of the prostate spread prostate cancer cells?
